District of Columbia, District of Columbia Clinical Trials
A listing of District of Columbia, District of Columbia clinical trials actively recruiting patient volunteers.
Found 95 clinical trials
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
- 0 views
- 19 Feb, 2024
- +162 other locations
Home Blood Pressure Study for Recent Stroke Survivors With High Blood Pressure *On Hold Due to Global Pandemic*
The purpose of this pilot study is to assess the feasibility of implementing a home blood pressure self-management program in a population of recent stroke survivors in the Washington, D.C. area. The investigators hypothesize that hypertensive stroke survivors in the Washington, DC area who participate in the Home Blood Pressure …
- 0 views
- 19 Feb, 2024
- 1 location
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Background Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and surgery. But survival rates are poor. Researchers think that the drug selinexor, when combined with chemotherapy and radiation, might help. Objective To learn the highest dose of selinexor that people with brain cancer can tolerate when given …
- 0 views
- 19 Feb, 2024
- 1 location
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant …
- 0 views
- 24 Nov, 2025
- 1 location
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
- 0 views
- 19 Feb, 2024
- +9 other locations
Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication
Prospective, multi-center, non-randomized study with consecutive, eligible subject enrollment at each site, for the evaluation of the ChEVAS System for Endovascular Repair of Complex Abdominal Aortic Aneurysms.
- 0 views
- 19 Feb, 2024
- +2 other locations
SPRINT Peripheral Nerve Stimulation for the Treatment of Back Pain
The purpose of this study is to compare standard of care treatments for back pain to electrical stimulation. Electrical stimulation is delivering small amounts of electricity to the nerves in your low back. This study will use a device called the SPRINT Peripheral Nerve Stimulation (PNS) System. The SPRINT PNS …
- 0 views
- 19 Feb, 2024
- +1 other locations
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
Background Psoriasis causes chronic inflammation in the body. Researchers want to see if a kind of vitamin B3 dietary supplement can help. This might lead to more treatment options. Objective To test if the dietary supplement nicotinamide riboside can improve immune system function in the blood and skin of people …
- 0 views
- 19 Feb, 2024
- 1 location
PB2452 in Ticagrelor-treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure
This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with PB2452 in patients who present with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure. Approximately 200 patients will be enrolled at approximately 200 centers worldwide. Patients with reported …
- 0 views
- 19 Feb, 2024
- +5 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.
- 0 views
- 19 Feb, 2024
- +16 other locations